# REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

> **NCT07594106** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 265 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Clear Cell Renal Cell Carcinoma (ccRCC)

## Interventions

- **DRUG:** REGN15505
- **DRUG:** REGN15505+Cemiplimab
- **DRUG:** REGN15505+REGN4336

## Key facts

- **NCT ID:** NCT07594106
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-25
- **Primary completion:** 2030-09-20
- **Final completion:** 2030-09-20
- **Target enrollment:** 265 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07594106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07594106, "REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07594106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*